ALEXION'S SOLIRIS PREVENTS REJECTION IN KIDNEY TRANSPLANTS.

Biotech BusinessVol. 22 Nbr. 7, July 2009

Linked as:

Summary


Clinical report

See the full content of this document

Extract


ALEXION'S SOLIRIS PREVENTS REJECTION IN KIDNEY TRANSPLANTS.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has announced that researchers presented early clinical and laboratory data on the potential role of terminal complement inhibition with...

See the full content of this document

Sponsored links




ver las páginas en versión mobile | web

ver las páginas en versión mobile | web

© Copyright 2012, vLex. All Rights Reserved.

Contents in vLex United States

Explore vLex

For Professionals

For Partners

Company